While tumor necrosis factor (TNF) deficiency is associated with a higher incidence of tuberculosis, excessive production of TNF is associated with an exaggerated inflammatory response that can result in mycobacterial immune reconstitution inflammatory syndrome (IRIS).
Immune reconstitution inflammatory syndrome (IRIS) is a paradoxical clinical worsening of a known condition—or the appearance of a new condition—after a patient with HIV initiates antiretroviral therapy (ART). Frequently associated with mycobacteria, which can cause tuberculosis (TB), among other diseases, IRIS typically requires treatment with corticosteroids. However, patients’ clinical response to corticosteroid treatment is not always adequate, and that challenge has clinicians looking to anti—tumor necrosis factor (TNF) therapies for alternatives.
While TNF deficiency is associated with a higher incidence of TB, excessive production of TNF is associated with an exaggerated inflammatory response that can result in mycobacterial IRIS. A new case report published in Open Forum Infectious Diseases suggests that biosimilar infliximab, an anti-TNF, could provide a therapeutic option for patients whose IRIS is refractory to corticosteroids.
The case report first discusses Patient 1, a 33-year-old African American man who was diagnosed with HIV 3 months prior to being admitted to the hospital with a high fever, where a culture confirmed the presence of drug-sensitive Mycobacterium tuberculosis. After 3 weeks of anti-TB therapy, the patient initiated anti-HIV treatment with raltegravir, emtricitabine, and tenofovir. After 4 weeks, the patient developed a fever and enlarged lymph nodes. When Patient 1 did not show clinical improvement after treatment with naproxen and methylprednisolone, and other possible pathogens had been ruled out, the clinicians initiated treatment with biosimilar infliximab, CT-P13 at a dose of 5 mg/kg every 2 weeks for a total of 3 infusions.
During the third infusion, Patient 1 experienced an anaphylactic reaction despite premedication with hydrocortisone and paracetamol (the reaction was resolved with adrenaline, hydrocortisone, and infused saline solution). In the weeks following his treatment with biosimilar infliximab, Patient 1’s fever resolved and his lymph nodes were no longer palpable.
The authors also report on Patient 2, a 44-year-old white woman diagnosed with HIV in 2003 who had not taken ART in the 2 years prior to her 2015 admission to the hospital with fever and diarrhea—the fever resolved after anti-TB therapy. Several weeks later, a biopsy of her colon yielded Mycobacterium bovis. After 5 weeks of antimycobaterial therapy, Patient 2 initiated anti-HIV therapy, but developed abdominal pain and symptoms indicating partial obstruction of the intestine that required hospitalization. Patient 2’s symptoms resolved with methylprednisolone, but after tapering the corticosteroid, she required several subsequent hospitalizations for a return of the partial obstruction of the intestine.
Because the corticosteroid could not be withdrawn without worsening Patient 2’s condition, the clinicians initiated treatment with biosimilar infliximab (CT-P13, as with Patient 1) at 5 mg/kg every 2 weeks for a total of 3 infusions. Patient 2’s clinical condition improved, and laboratory values returned to normal with no indications of a relapse of mycobacterial disease. Methylprednisolone was tapered and eventually withdrawn 6 weeks after the first infliximab dose with no difficulty. No adverse events related to treatment with infliximab were recorded for Patient 2.
A meta-analysis of 40 studies and 1048 cases showed that tuberculosis-associated IRIS was reported in 18% of patients with HIV who were initiating ART, and that a 2% mortality rate and a 25% morbidity rate were directly attributable to TB-associated IRIS. “Treatment for the more severe and life-threatening clinical forms of IRIS has not undergone any innovative changes in recent decades beyond the use of corticosteroids,” the authors note. While their experience in using biosimilar infliximab with patients who have HIV is limited, and while Patient 1’s anaphylactic reaction to treatment is noteworthy, they believe that biosimilar infliximab could be a promising alternative for patients who have severe, corticosteroid-refractory mycobacterial IRIS.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.